PP
RXRX icon

PDS Planning’s Recursion Pharmaceuticals RXRX Stock Holding History

PDS Planning’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89K Hold
24,246
– – 0.01% 602
2026
Q1 		$74.4K Buy
24,246
+10,558
+77% +$40.8K ﹤0.01% 552
2025
Q4 		$56K Hold
13,688
– – ﹤0.01% 545
2025
Q3 		$66.8K Buy
13,688
+1,240
+10% +$6.51K ﹤0.01% 533
2025
Q2 		$63K Sell
12,448
-640
-5% -$3.14K ﹤0.01% 508
2025
Q1 		$69.2K Buy
+13,088
New +$95.4K 0.01% 467

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

PDS Planning's RXRX Position: Q2 2026 in Review

PDS Planning held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 24,246 shares worth $89K. The position accounts for 0.01% of the portfolio, ranked #602.

PDS Planning first reported a position in RXRX in Q1 2025 and has held it in 6 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • PDS Planning held 24,246 shares of Recursion Pharmaceuticals worth $89K as of Q2 2026.
  • PDS Planning left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
  • Recursion Pharmaceuticals made up 0.01% of PDS Planning's portfolio in Q2 2026, its #602 holding.
  • PDS Planning first reported a position in Recursion Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on PDS Planning's 13F filing for Q2 2026, filed 5 Aug 2026.